Get the Stockscreener App
38.82
2.21%
0.84
Phibro Animal Health Corp stock is traded at $38.82, with a volume of 186.99K.
It is up +2.21% in the last 24 hours and up +9.97% over the past month.
Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.
See More
Previous Close:
$37.98
Open:
$38.04
24h Volume:
186.99K
Relative Volume:
0.79
Market Cap:
$1.58B
Revenue:
$1.50B
Net Income/Loss:
$95.23M
P/E Ratio:
16.68
EPS:
2.328
Net Cash Flow:
$12.77M
1W Performance:
+1.36%
1M Performance:
+9.97%
6M Performance:
-27.95%
1Y Performance:
+0.65%
1-Day Range:
$37.24
$38.94
1-Week Range:
$36.53
$39.64
52-Week Range:
$28.25
$60.08
Phibro Animal Health Corp Stock (PAHC) Company Profile
Name
Phibro Animal Health Corp
Sector
Phone
201-329-7300
Address
GLENPOINTE CENTRE EAST, 3RD FLOOR, TEANECK, NJ
Compare PAHC vs TAK, TEVA, HLN, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PAHC
Phibro Animal Health Corp
|
38.82 | 1.58B | 1.50B | 95.23M | 12.77M | 2.328 |
TAK
Takeda Pharmaceutical Co Adr
|
19.67 | 62.84B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
41.50 | 48.40B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
10.13 | 44.55B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
79.38 | 32.80B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
533.12 | 22.87B | 3.17B | 1.29B | 1.01B | 27.09 |
Phibro Animal Health Corp Stock (PAHC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-26 | Initiated | Citigroup | Neutral |
| Jul-07-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Jun-16-25 | Upgrade | BNP Paribas Exane | Underperform → Neutral |
| Sep-10-24 | Initiated | JP Morgan | Neutral |
| Dec-07-23 | Initiated | Exane BNP Paribas | Underperform |
| Dec-21-22 | Initiated | ROTH Capital | Buy |
| Jul-25-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-10-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Nov-18-21 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-05-21 | Resumed | Credit Suisse | Neutral |
| Jul-07-21 | Downgrade | Barclays | Equal Weight → Underweight |
| Aug-06-20 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Feb-06-20 | Downgrade | Gabelli & Co | Buy → Hold |
| Jan-28-20 | Upgrade | Barclays | Underweight → Equal Weight |
| Sep-05-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Aug-29-19 | Reiterated | BofA/Merrill | Underperform |
| Jun-11-19 | Initiated | Barclays | Underweight |
| May-23-19 | Initiated | Guggenheim | Neutral |
| May-09-19 | Upgrade | Gabelli & Co | Hold → Buy |
| Aug-23-17 | Resumed | BofA/Merrill | Underperform |
| Jun-02-17 | Downgrade | Credit Suisse | Outperform → Neutral |
| Dec-15-16 | Initiated | Piper Jaffray | Overweight |
| Nov-11-16 | Downgrade | Macquarie | Neutral → Underperform |
| Nov-10-16 | Downgrade | Gabelli & Co | Buy → Hold |
| Apr-11-16 | Reiterated | Guggenheim | Buy |
| Feb-04-16 | Initiated | Credit Suisse | Outperform |
| Jan-15-16 | Downgrade | Barclays | Overweight → Underweight |
| Sep-30-15 | Initiated | Gabelli & Co | Buy |
| Apr-24-15 | Reiterated | Barclays | Overweight |
| Apr-21-15 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| May-06-14 | Initiated | Barclays | Overweight |
View All
Phibro Animal Health Corp Stock (PAHC) Latest News
Reasons to Add STE Stock to Your Portfolio Right Now - Zacks Investment Research
Haemonetics Gains 149.3% in a Year: What's Driving the Rally? - Zacks Investment Research
Is it Apt to Retain Medtronic Stock in Your Portfolio Now? - Zacks Investment Research
Is it Apt to Retain Prestige Consumer Stock in Your Portfolio Now? - Zacks Investment Research
Is it the Right Time to Hold TNDM Stock in Your Portfolio? - Zacks Investment Research
Is it the Right Time to Add Phibro Stock to Your Portfolio? - Zacks Investment Research
Encompass Health Expands Rehab Footprint With New Maine Hospital - Zacks Investment Research
Is This the Right Time to Add TMO Stock to Your Portfolio? - Zacks Investment Research
Neogen Stock Rallies 83% YTD: What's Driving the Surge? - Zacks Investment Research
Should You Continue to Hold IART Stock in Your Portfolio? - Zacks Investment Research
Chewy's Vet Care Posts Triple-Digit Growth as Clinic Scale Builds - Zacks Investment Research
Is This the Right Time to Add Labcorp Stock to Your Portfolio? - Zacks Investment Research
Phibro Animal Health (NasdaqGM:PAHC) Stock Forecast & Analyst Predictions - Simply Wall Street
Phibro Animal Health CFO David Glenn Granted 3,482 Shares, Increasing Holdings to 54,959 - Kalkine Media
Phibro Animal Health (PAHC) updates CFO’s 3,482-unit stock grant - Stock Titan
COO stock award takes Phibro Animal Health (PAHC) stake to 38,275 units - Stock Titan
Big Phibro Animal Health (PAHC) investor lines up stock sale plan - Stock Titan
Phibro Animal Health Corporation to Participate in Morgan Stanley Annual Global Healthcare Conference - Yahoo Finance
Phibro Animal Health Corporation to Participate in Morgan Stanley Annual Global Healthcare Conference - Business Wire
Phibro Animal Health (PAHC) Sets 2027 Guidance, Is The Stock Still A Bargain? - Yahoo Finance
Phibro Animal Health Corp (PAHC) Shares Surge 3.9% -- What GF Sc - GuruFocus
Should Value Investors Buy Phibro Animal Health (PAHC) Stock? - Yahoo Finance
Understanding Phibro (PAHC) Reliance on International Revenue - Yahoo Finance
Teleconferência de Resultados do 4º Trimestre Fiscal e do Ano Fiscal de 2026 da PAHC: Crescimento das Vendas, Guidance para 2027 e Risco Brasil - TradingKey
Phibro Animal Health Corporation Class A (PAHC) Peer Comparison – Compare with Others - Value Research
Phibro Animal Health Corporation Class A (PAHC) Key Financial Ratios – Valuation, Profitability & More - Value Research
Phibro Animal Health Corporation Class A (PAHC) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
PAHC Q2 Deep Dive: Diverse Portfolio Offsets Regulatory and Margin Headwinds - Yahoo Finance
Phibro Animal Health declares $0.12 quarterly dividend - scanx.trade
Earnings call transcript: Phibro Animal Health tops Q4 2026 estimates - Investing.com
Earnings call transcript: Phibro Animal Health tops Q4 2026 estimates By Investing.com - Investing.com India
Phibro Q4 FY26 slides: record year, margins expand on Zoetis deal - investing.com
PAHC SWOT Analysis: Strong Growth Potential Amidst Valuation Con - GuruFocus
Is Phibro Animal Health Corp (PAHC) Overvalued After Q4 Earnings - GuruFocus
Phibro Animal Health Corp reports results for the quarter ended June 30Earnings Summary - TradingView
Phibro Animal Health Submits Annual 10-K Report for Fiscal Year Ending June 30, 2026 - Kalkine Media
(PAHC) Phibro Animal Health Expects Fiscal 2027 Revenue Range $1.55B$1.60B, vs. FactSet Est of $1.55B - marketscreener.com
Earnings Flash (PAHC) Phibro Animal Health Posts Fiscal Q4 Revenue $396.7M, vs. FactSet Est of $381.2M - marketscreener.com
Phibro Animal Health Corporation (PAHC) Stock Rises on Q4 2026 Earnings - Quiver Quantitative
Phibro Animal Health jumps 5% on strong Q4 earnings and guidance beat - Investing.com
PHIBRO ANIMAL HEALTH CORP FY 2026: Revenue $1.52B, EPS $2.43— 10-K Summary - TradingView
Phibro: Fiscal Q4 Earnings Snapshot - KVUE
Phibro Animal Health Corporation Reports Fourth Quarter and Fiscal Year Results, Provides Financial Guidance - Yahoo Finance
Phibro Animal Health sets FY27 adj EPS $3.41-$3.59, beats est - scanx.trade
Phibro Animal Health Corporation Reports Fourth Quarter and Fiscal Year Results, Provides Financial Guidance - Business Wire
JPMorgan reiterates Phibro Animal Health stock rating on solid outlook By Investing.com - Investing.com Nigeria
JPMorgan reiterates Phibro Animal Health stock rating on solid outlook By Investing.com - Investing.com Canada
JPMorgan reiterates Phibro Animal Health stock rating on solid outlook By Investing.com - Investing.com India
Earnings To Watch: Phibro Animal Health (PAHC) Reports Q2 Results Tomorrow - Yahoo Finance
Phibro Animal Health Corp (PAHC) Shares Surge 3.2% -- What GF Sc - GuruFocus
Phibro Animal Health Corp Stock (PAHC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Phibro Animal Health Corp Stock (PAHC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Weinstein Judith | Officer |
Aug 04 '26 |
Proposed Sale |
36.60 |
472 |
17,275 |
0 |
| Bendheim Daniel M | Officer |
Aug 04 '26 |
Proposed Sale |
36.60 |
486 |
17,787 |
0 |
| Escudero Lisa Ann | Officer |
Aug 04 '26 |
Proposed Sale |
36.60 |
265 |
9,699 |
0 |
| David Glenn | Officer |
Aug 04 '26 |
Proposed Sale |
36.60 |
840 |
30,744 |
0 |
| BENDHEIM JACK | Officer |
Aug 04 '26 |
Proposed Sale |
36.60 |
2,303 |
84,288 |
0 |
| Miller Larry Lee | Officer |
Aug 04 '26 |
Proposed Sale |
36.60 |
635 |
23,241 |
0 |
| BFI Co. LLC | 10% Owner |
Jun 16 '26 |
Proposed Sale |
31.87 |
281,600 |
8,974,592 |
0 |
| CORCORAN E THOMAS | Director |
May 29 '26 |
Buy |
31.77 |
10,000 |
317,700 |
41,459 |
| BENDHEIM JACK | President and CEO |
May 07 '26 |
Sale |
48.49 |
4,528 |
219,568 |
56,152 |
| BENDHEIM JACK | President and CEO |
May 06 '26 |
Sale |
57.37 |
7,040 |
403,850 |
60,680 |
0.01%
1.99%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):